Odanacatib Inhibits Resistin-induced Hypertrophic H9c2 Cardiomyoblast Cells Through LKB1/AMPK Pathway

AUTOR(ES)

Zheng, Xian, Liu, Huzi, Cheng, Guanchang, Luo, Jianwei, Ye, Qunhui, Deng, Yongzhi, Wu, Lin

FONTE

Braz. arch. biol. technol.

DATA DE PUBLICAÇÃO

17/08/2017

RESUMO

ABSTRACT Odanacatib (ODN) is a selective inhibitor of cathepsin K. The cysteine protease cathepsin K has been implicated in cardiac hypertrophy. Resistine is an adipokine which is identified to promote cardiac hypertrophy. Here, we hypothesize that ODN mitigates resistin-induced myocyte hypertrophy. Cell surface area and protein synthesis were measured after treatment with resistin and ODN in H9c2 cells. The expression of cardiomyocyte hypertrophy marker BNP and β-MHC was detected by RT-qPCR. The expression and phosphorylation of AMPK and LKB1 were analyzed with Western blot. Resistin could significantly increase cardiomyocyte cell surface area, protein synthesis, and embryonic gene BNP and β-MHC expression, inhibit phosphorylation of AMPK and LKB1. ODN could significantly reverse the effects of resistin. Collectively, our data suggest that ODN can inhibit cardiomyocyte hypertrophy induced by resistin and the underlying mechanism may be involved in LKB1/AMPK pathway.

Documentos Relacionados

• BMP4 Induces Cardiomyocyte Hypertrophy Through the Activation of ERK 1/2 Signaling Pathway in H9c2 Cells
• CIRBP protects H9C2 cells against myocardial ischemia through inhibition of NF-κB pathway
• Hydrogen sulfide protects H9c2 cardiomyoblasts against H2O2-induced apoptosis
• Protective effect of Rheum turkestanikum root against doxorubicin-induced toxicity in H9c2 cells
• Emodin protects H9c2 cells from hypoxia-induced injury by up-regulating miR-138 expression